Tea Catechins for Health & Longevity
Evidence Review created on 09/25/2026 using AI4L + evidence-mcp / Grok 4
Also known as: Green Tea Catechins, GTCs, Tea Polyphenols, Green Tea Polyphenols, Camellia sinensis Catechins
Motivation
Tea catechins are plant compounds concentrated in the leaf of Camellia sinensis, the plant used for green tea, when that leaf is heated before it browns. The most abundant is the main bitter compound in the cup. A cup delivers a modest amount. A capsule can deliver several cups. Longevity-oriented adults have looked at them because trials find small changes in cholesterol and blood pressure, and because tea drinking tracks with longer life in East Asian studies.
The leaf was a medicinal infusion in China long before it was an everyday drink. Capsules came later, as a way to bottle the catechin intake of several cups. Safety splits along that line. Liver-enzyme rises cluster with high-dose extracts taken as a solid dose apart from food, and are rarely described with ordinary brewed tea. The same compounds bind iron from plant foods and can sharply reduce blood levels of certain heart drugs.
This review examines the human evidence on those effects and on longer-term disease risk, and sets it beside liver, digestive, and drug-interaction harms. It treats brewed tea and concentrated extracts as related but not interchangeable, because dose and dosing conditions change both any benefit and the chance of harm.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
High-level commentary and narrative sources on tea catechins, green tea extracts, and the catechin-rich drink, outside systematic reviews and reference databases.
-
Polyphenol-Rich Diets and Brain Aging - FoundMyFitness
A FoundMyFitness topic on a calorie-restricted diet that added several cups of green tea. It explains how green tea catechins sit inside a broader polyphenol pattern studied for glucose control and hippocampal volume.
-
The Potential Downsides to Coffee and 6 Healthy Alternatives That Provide the Same Benefits - Lindsay Christensen
On Chris Kresser’s site, a section on green and black tea covers epigallocatechin gallate, other catechins, and L-Theanine as the reasons tea is discussed as a lower-caffeine alternative to coffee.
-
Brain-Protective Effects of Green Tea - Sheldon Cannon
A Life Extension magazine article on catechins and brain aging. It reviews proposed mechanisms and the observational association between regular green tea drinking and fewer cognitive disorders.
-
Antioxidants Rescue Cognitive Decline in Mice - Arkadi Mazin
Lifespan.io’s report of a mouse study in which epigallocatechin gallate, alone and with curcumin, lessened memory loss from oxidative stress. Mechanism context only, not human evidence.
-
Green Tea (Camellia sinensis): A Review of Its Phytochemistry, Pharmacology, and Toxicology - Zhao et al., 2022
A narrative review of leaf chemistry, proposed actions, and toxicology, including the liver signal from concentrated extracts. It is not a systematic review.
Searches of Peter Attia’s site found only a brief mention of green tea catechins inside an article on flavonoid diversity, not a discussion in substantial depth, so it is not listed. No Huberman Lab page discussing tea catechins by name in substantial depth was found. The five items above are the sources that met the depth bar.
Grokipedia
-
Grokipedia’s green tea article describes how unoxidized Camellia sinensis leaves keep catechins, led by epigallocatechin gallate, and summarizes processing, composition, and the health claims attached to that chemistry.
Examine
-
Examine’s monograph on the catechin-rich extract covers dose, cardiometabolic outcomes, and liver damage. It states that one cup of green tea supplies about 50 mg of epigallocatechin gallate equivalents.
ConsumerLab
-
Green Tea Review: Tea Bags, Loose Leaf Tea, Matcha Powders, and Supplements
ConsumerLab’s green tea review compares epigallocatechin gallate, caffeine, and contaminants across bags, matcha, and capsules. The public summary reports a wide spread in catechin dose per serving.
Systematic Reviews
These systematic reviews pool randomized trials of green tea or epigallocatechin gallate (EGCG, the main tea catechin) on low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, blood pressure, weight, glucose, cancer, and liver safety, including GRADE (a framework for rating how sure a review is in its result) ratings of blood pressure and weight.
-
The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis. - Zamani et al., 2022
Fifty-five randomized trials found lower total and LDL cholesterol, fasting glucose, and diastolic pressure, plus a small HDL cholesterol rise.
-
Effect of green tea supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials. - Rezaei et al., 2025
Thirty-six randomized trials found about a 1 mmHg lower systolic and diastolic pressure, larger when starting pressure was already high.
-
Effects of green tea supplementation on obesity indices and adipokines in adults: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials - Dehzad et al., 2025
Green tea supplementation reduced body weight by about 0.7 kg and produced smaller reductions in waist, body mass index, and body fat.
-
Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis. - Zhang et al., 2025
Pooled studies linked green tea to a relative risk (compared with non-users) of 0.91 and EGCG to 0.72, clearest for prostate and oral cancer.
-
The safety of green tea and green tea extract consumption in adults - Results of a systematic review. - Hu et al., 2018
Across 159 human studies, liver adverse events rose with large bolus (all-at-once) doses of catechin-rich extracts and were not seen with brewed tea.
Mechanism of Action
Tea catechins are flavan-3-ols, a flavonoid class. EGCG usually accounts for about half of the catechins in green tea and is a promiscuous binder, not a selective drug. It scavenges reactive oxygen species and can turn on nuclear factor erythroid 2–related factor 2 (Nrf2, a switch for antioxidant enzymes) and AMP-activated protein kinase (AMPK, a cellular energy sensor). In the gut the mixture modestly reduces fat absorption and chelates non-heme iron (iron from plant foods, not from meat). Effects on blood vessels are tied to nitric oxide in the vessel lining.
After an oral dose, blood levels peak in about 1.3–1.6 hours. Elimination half-life is about 3.4 hours for EGCG, 1.7 hours for epigallocatechin, and 2.0 hours for epicatechin (Lee et al.). Clearance is methylation by catechol-O-methyltransferase (COMT, an enzyme that adds a methyl group), plus glucuronidation and sulfation (sugar and sulfate attachments). The liver sees a high first-pass concentration (before it circulates), which is the leading explanation for enzyme rises when a large capsule is absorbed at once. Levels after an oral dose are highest in the gut and liver, not in blood or brain. In the liver the same molecule can also create oxidative stress, a competing account of enzyme rises beside the size of the dose. A once-daily 800 mg EGCG bolus also raised later EGCG exposure by more than 60%, whereas 400 mg twice daily did not (Chow et al.). Cytochrome P450 (CYP, a family of drug-metabolizing enzymes) is not the main clearance path.
Historical Context & Evolution
Tea drinking began in China. Written medicinal use of the leaf long predates its role as a daily social drink in East Asia. Green processing, by steaming or pan-firing, stops oxidation and keeps the catechins that black tea converts into theaflavins and thearubigins (oxidized black-tea pigments). Twentieth-century laboratory work, especially on EGCG, moved attention from the cup to isolated extracts proposed first for cancer prevention and later for cholesterol, weight, and blood sugar.
An early one-year trial in men with high-grade prostate intraepithelial neoplasia (abnormal prostate cells that are not yet cancer) reported one cancer among 30 men on catechin capsules and nine among 30 on placebo (Bettuzzi et al.). Later trials have not spoken with one voice, so that result is part of the record rather than a closed case. In parallel, case reports and then a year-long trial of 843 mg EGCG daily made liver injury from high-dose extracts a central safety question, while the large mortality studies kept measuring brewed tea (Dostal et al., Abe et al.). What changed is the dose form. A cup and a capsule are not the same exposure, and neither body of results is the last word.
Expected Benefits
High 🟩 🟩 🟩
Lower LDL and Total Cholesterol
Green tea supplementation lowers LDL cholesterol and total cholesterol by a small amount across dozens of randomized trials. A pool of 55 trials found LDL cholesterol about 5.8 mg/dL lower and total cholesterol about 7.6 mg/dL lower, with HDL cholesterol about 1.9 mg/dL higher (Zamani et al.). In adults with overweight, catechin supplements also lowered triglycerides (Wang et al.). The shift is replicated, and it is too small to replace a drug aimed at a much larger cholesterol change.
Magnitude: About 5.8 mg/dL lower LDL cholesterol and 7.6 mg/dL lower total cholesterol across 55 randomized trials, with HDL cholesterol about 1.9 mg/dL higher.
Slightly Lower Blood Pressure ⚠️ Conflicted
Randomized trials of green tea find a very small drop in blood pressure. A dose-response meta-analysis of 36 trials reported systolic and diastolic pressure each about 1.1 mmHg lower, with a larger shift when starting systolic pressure was at least 120 mmHg (Rezaei et al.). A meta-analysis in adults with overweight did not find a significant blood-pressure effect (Wang et al.). The net reading is a roughly 1 mmHg average reduction that is clearer when pressure starts high and is not dependable in every overweight group.
Magnitude: About 1.1 mmHg lower systolic and 1.1 mmHg lower diastolic pressure across 36 randomized trials.
Small Loss of Body Weight
Green tea extracts produce a small loss of body weight in randomized trials, not a large change in body composition. A dose-response meta-analysis found body weight about 0.74 kg lower, body mass index (BMI, weight adjusted for height) about 0.29 kg/m² lower, and waist about 1.0 cm lower (Dehzad et al.). A pool of 59 trials also found lower body weight and body-fat percentage (Asbaghi et al.). Proposed mechanisms are slightly higher fat oxidation and slightly lower fat absorption.
Magnitude: About 0.74 kg lower body weight, 0.29 kg/m² lower BMI, and 1.0 cm lower waist circumference in a dose-response meta-analysis of randomized trials.
Small Glucose Shifts ⚠️ Conflicted
Fasting glucose and glycated hemoglobin move only slightly, and not in every population. Across mixed trials, fasting glucose was about 1.7 mg/dL lower and glycated hemoglobin about 0.15 points lower (Zamani et al.). A type 2 diabetes meta-analysis reported a clearer fasting-glucose reduction (Jia et al.). A metabolic-syndrome meta-analysis found no significant overall glycemic effect (Ghoflchi et al.). The net reading is a very small average reduction in broad and diabetes pools that disappears in the metabolic-syndrome pool.
Magnitude: About 1.7 mg/dL lower fasting glucose and 0.15 percentage points lower glycated hemoglobin in a 55-trial pool; no significant glycemic effect in a metabolic-syndrome meta-analysis.
Medium 🟩 🟩
Lower Mortality with Habitual Green Tea Drinking
Eight Japanese cohorts found a lower hazard of death (chance of dying versus lighter drinkers) at five or more cups a day versus under one: 0.90 in men and 0.82 in women (Abe et al.). Heart and stroke deaths moved the same way. These studies measured brewed tea, not catechin capsules.
Magnitude: Relative hazard of all-cause death 0.90 in men and 0.82 in women for five or more cups a day versus under one cup, in eight pooled Japanese cohorts.
Low 🟩
Fewer Cognitive Disorders ⚠️ Conflicted
Observation, not capsule trials, ties green tea to less cognitive impairment. Eighteen studies (58,929 people) found an odds ratio (odds versus non-drinkers) of 0.63 (Zhou et al.). It appeared in Asian cohorts, not European ones. The net reading is a lower pooled risk that European studies do not show.
Magnitude: Odds ratio 0.63 for cognitive impairment in 18 observational studies (58,929 people); the European subgroup showed no association.
Lower Cancer Occurrence ⚠️ Conflicted
Green tea was tied to a relative cancer risk of 0.91 in mixed cohorts and trials (Zhang et al.). An early trial found 1 prostate cancer on catechins versus 9 on placebo (Bettuzzi et al.). Later work has not repeated it. The net reading is unsettled, not proven prevention.
Magnitude: Relative cancer risk 0.91 for green tea and 0.72 for EGCG in one mixed meta-analysis; 1 versus 9 prostate cancers at one year in a 60-man trial that later work has not consistently repeated.
Speculative 🟨
Slower Human Aging via Cellular Energy Sensing
Cell and animal work links catechins to cellular energy sensing and antioxidant switches. No human trial has measured a slower rate of aging, so the basis is mechanistic only.
Benefit-Modifying Factors
-
COMT genotype: COMT variants may change how fast gallated catechins are methylated and cleared. Clinical evidence for a genotype-based dose change is inconsistent.
-
Baseline lipids and pressure: The cholesterol shift is a few mg/dL, so adults with higher starting LDL cholesterol have more absolute room for it. Blood-pressure shifts are larger when systolic pressure starts at or above 120 mmHg.
-
Sex: Blood-pressure meta-analyses have reported slightly larger average shifts in women. The largest liver-safety trial enrolled postmenopausal women, so the benefit data are not male-specific.
-
Metabolic disease: Fasting-glucose changes are more evident in type 2 diabetes trials and were null overall in a metabolic-syndrome pool. Body-weight trials cluster in adults with overweight.
-
Age: Mortality associations come from adult and older cohorts drinking tea, not from extract trials in advanced age. Older adults more often take drugs that share gut transporters with catechins.
Potential Risks & Side Effects
High 🟥 🟥 🟥
Liver Enzyme Elevation from Concentrated Extracts
Concentrated extracts can raise liver enzymes. At 843 mg EGCG daily, alanine aminotransferase (ALT, a liver enzyme) rose in 6.7% of women versus 0.7% on placebo, and 1.3% had a serious ALT event (Dostal et al.). Odds of a moderate abnormality were seven times the placebo rate, then fell after stopping and rose on restart (Yu et al.). Across 159 studies, liver events tracked large extract boluses, not brewed tea. The safe level derived for solid doses was 338 mg EGCG a day (Hu et al.).
Magnitude: ALT elevation in 6.7% versus 0.7% at 843 mg EGCG daily for one year, and about sevenfold higher odds of moderate or worse liver-test abnormalities.
Loss of Nadolol Effect
Green tea can remove most of the absorbed dose of nadolol, a beta-blocker (a drug that slows heart rate and lowers blood pressure) that depends on a gut uptake transporter. In 10 volunteers, two weeks of green tea cut nadolol exposure by 85% and blunted its effect on systolic pressure (Misaka et al.). A single cup still cut exposure, including when tea was taken one hour earlier (Misaka et al.). The transporter is organic anion-transporting polypeptide 1A2 (OATP1A2, a protein that carries some drugs from the gut into blood).
Magnitude: Nadolol exposure fell by 85% after two weeks of green tea in 10 volunteers, with a weaker blood-pressure effect from the drug.
Medium 🟥 🟥
Nausea ⚠️ Conflicted
Nausea is the clearest digestive adverse event of high-dose extracts. In a year-long trial of 843 mg EGCG daily, nausea was reported by 10.2% on the extract and 4.8% on placebo (Dostal et al.). Events were mostly mild, and diarrhea was less common on the extract than on placebo. Shorter trials listed gastric discomfort at rates similar to placebo (Chow et al.). The net reading is excess nausea in the long high-dose trial, not a higher rate of every digestive symptom.
Magnitude: Nausea in 10.2% versus 4.8% during one year of 843 mg EGCG daily.
Dermatologic Adverse Events
The year-long 843 mg EGCG trial reported more dermatologic adverse events on the extract than on placebo, at the border of statistical significance (Dostal et al.). The events were part of a mostly mild adverse-event profile. This is one trial, not a repeated rash syndrome.
Magnitude: Dermatologic adverse events in 3.3% versus 1.5% at 843 mg EGCG daily (18 versus 8 participants), at borderline statistical significance.
Low 🟥
Less Non-Heme Iron Absorbed with Meals ⚠️ Conflicted
Tea with a meal cuts non-heme iron absorption (Lazrak et al.). Purified EGCG cut it by 14% at 150 mg and 27% at 300 mg (Ullmann et al.). The net reading is a larger drop from tea taken with iron than from a modest EGCG capsule.
Magnitude: Tea with the iron dose lowers absorption; purified EGCG lowered it by 14% at 150 mg and 27% at 300 mg. No single rate of new iron deficiency is established.
Sleep Disruption from Caffeine in the Product
Caffeine, not the catechin, is what disturbs sleep. Brewed green tea often supplies tens of milligrams per cup, while one decaffeinated trial extract had under 16 mg per day (Dostal et al.). Insomnia risk follows the product’s caffeine, not a fixed catechin effect.
Magnitude: Caffeine dose varies from a few milligrams in decaffeinated extracts to tens of milligrams per cup of brewed tea. The literature does not report one insomnia rate for all catechin products.
Speculative 🟨
Risk-Modifying Factors
-
COMT and liver risk: Faster or slower methylation by COMT may change internal catechin exposure. Genotype is not yet a practical predictor of who will develop an ALT rise.
-
Fasting bolus versus fed dose: Liver events cluster with large solid doses taken apart from food. The same nominal EGCG amount in a beverage with food has a wider observed safe level in the safety review.
-
Sex: The quantified ALT signal comes from postmenopausal women. Case reports include men, so male sex is not protective. Iron loss matters more where menstrual iron loss is already high.
-
Existing liver disease: Adults with prior liver disease, or a prior extract-related enzyme rise, have less reserve if ALT climbs again. A normal baseline ALT did not prevent new rises in the Minnesota cohort.
-
Age and drug burden: Older adults more often use nadolol or other transporter-dependent drugs and have less hepatic reserve. The mortality cohorts of older tea drinkers do not describe the extract liver signal.
Key Interactions & Contraindications
-
Nadolol (beta-blocker): Severity is high. Two weeks of green tea cut exposure by about 85% and blunted the blood-pressure effect. Taking tea one hour earlier still reduced exposure. The described workaround is to use a different rate-control drug instead of combining them.
-
Iron supplements and iron-rich meals: Severity is caution. Non-heme iron absorption falls when tea is swallowed with the dose. Separating catechins from iron by at least one to two hours, and checking ferritin, mitigates this.
-
Other blood-pressure drugs (lisinopril, amlodipine): Severity is monitor. Any added pressure drop from catechins is about 1 mmHg in trial pools. Relevant mainly if pressure is already low.
-
Drugs with liver toxicity (acetaminophen at high doses, amiodarone, isoniazid): Severity is caution. The concern is additive liver stress, not a proven pharmacokinetic clash (how the drug is handled). An ALT check is the described precaution if an extract is added.
-
Anticoagulants (drugs that slow blood clotting, such as warfarin): Severity is monitor. Case reports describe a change in clotting time, not a measured bleed rate. An international normalized ratio (INR, a clotting-time measure) check is the described precaution.
-
Caffeine and other stimulants: Severity is caution, and only if the catechin product itself contains caffeine. The consequence is a stimulant effect or sleep loss. A decaffeinated extract removes that overlap.
Populations who should avoid Tea Catechins:
- Adults with active liver disease, or any prior ALT rise attributed to a green tea extract, including a value above the laboratory reference range during earlier use
- Pregnancy, for concentrated extracts; ordinary cups of tea are a separate, lower catechin exposure
- Adults who require nadolol, because catechins can remove most of that drug’s exposure
Risk Mitigation Strategies
-
Extracts taken with food: A dose taken with a meal avoids the fasting absorption peak linked to liver-enzyme rises. This mitigates extract-related liver injury.
-
Solid doses nearer 338 mg EGCG: The safety review’s observed safe level for a solid bolus was 338 mg EGCG per day. The 843 mg trial dose is where ALT rises were measured. This mitigates liver injury.
-
Enzyme recheck if warning symptoms appear: Yellowing of the skin or eyes, dark urine, or unusual tiredness is the point at which described protocols stop the extract and repeat ALT. This limits progression of liver injury.
-
Separation from iron and no nadolol: One to two hours away from iron supplements, and no nadolol co-use. This mitigates lost iron absorption and loss of nadolol effect.
-
ALT recheck at about four weeks: A baseline enzyme panel plus a repeat about four weeks after an extract starts catches a rise while stopping still reverses it. This mitigates unrecognized liver injury.
-
Decaffeinated extract when sleep is fragile: Removing caffeine mitigates insomnia without removing catechins. It does not mitigate the liver signal of a high EGCG dose.
Therapeutic Protocol
-
Brewed-tea pattern: Cohorts and many trials use about three to five cups of green tea daily. Catechin yield varies widely with leaf and steep, often on the order of a few hundred milligrams.
-
Extract pattern: Trial capsules often supply about 300–500 mg EGCG daily with meals. The 800 mg range is the dose at which liver-enzyme rises became measurable in a large trial.
-
Competing approaches: Beverage-first use is the exposure in mortality cohorts. Extract-first use is the exposure in most supplement trials. Neither is treated as the default.
-
Sources of each pattern: Everyday green-tea drinking is cultural, not a single clinic’s protocol. High-dose capsule regimens were developed in cancer-prevention trials such as Bettuzzi’s and the Minnesota study.
-
Time of day: Morning and midday, with food, keeps any caffeine away from sleep and avoids a fasting peak. Evening extract doses are the pattern linked to sleep complaints when caffeine remains.
-
Split dosing: EGCG’s half-life is about 3.4 hours. Twice daily with meals is the pattern used when the daily amount is large, and it produced less accumulation than one 800 mg bolus.
-
COMT: Variants may change methylation of gallated catechins. They are not used to set a catechin dose, because a genotype-specific clinical dose is not established.
-
Sex: The clearest ALT signal was measured in postmenopausal women. Blood-pressure pools have reported slightly larger average shifts in women. Men use the same liver caution.
-
Age: No separate extract dose is established for advanced age. Older adults more often use interacting drugs and have less liver reserve, which argues for the lower end of the extract range.
-
Baseline markers: Higher starting LDL cholesterol or blood pressure leaves more room for the small average shifts. A normal starting ALT does not remove the need for a follow-up enzyme test.
-
Existing conditions: Glucose data matter most in type 2 diabetes. Existing liver disease raises the cost of an enzyme rise and is a setting in which extracts are avoided.
Discontinuation & Cycling
-
How long: Brewed tea is a long-term dietary pattern. Extract trials run from weeks to one year. Nothing in the evidence requires lifelong extract use.
-
One product, one stop: Tea catechins are a single mixture, not separate agents with separate stop rules. The cup or the capsule is stopped as a unit.
-
Withdrawal: No withdrawal syndrome is described. ALT that rose on an extract generally falls after the extract is stopped, and it rose again when the extract was restarted.
-
Taper: No taper is described. Stopping is immediate. If enzymes had risen, they are rechecked after stopping rather than during a dose reduction.
-
Cycling: Cycling to preserve an effect is not established. Pausing a high-dose extract is a liver-safety habit, not a proven way to maintain efficacy.
Sourcing and Quality
-
EGCG on the label: Useful products state milligrams of EGCG or total catechins per serving. ConsumerLab’s tests found cup-level EGCG ranging from under 10 mg to over 100 mg.
-
Third-party testing: United States Pharmacopeia (USP) or NSF International certification, or another catechin and contaminant assay, is the practical check. Defined trial extracts include Polyphenon E and Sunphenon. Membership labs such as ConsumerLab sell access to product-level results.
-
Decaf versus caffeinated: Decaffeinated extracts remove most caffeine. Brewed tea and matcha do not. The liver issue is the catechin dose, not the caffeine.
-
Leaf versus brew: Powdered whole leaf, including matcha, delivers metals that brewing would leave in the spent leaf. Lead, when present, is mostly retained in the leaf rather than the liquor.
-
Fasting capsules: A dry bolus on an empty stomach is the condition tied to higher internal dose and liver events. Extracts taken with food, or catechins in a drink, are the lower-exposure forms.
Practical Considerations
-
Time to effect: Lipid, weight, and glucose trials generally measure outcomes at 8–12 weeks, not after a few days. Mortality associations reflect years of tea drinking.
-
Pitfalls: Taking a high-dose capsule while fasting; reading a cup-of-tea study as if it were an 800 mg extract; expecting multi-kilogram weight loss from catechins alone.
-
Regulatory status: In the United States, oral tea catechins are dietary supplements, not drugs approved to treat disease. A topical catechin ointment is a separate approved product for genital warts.
-
Cost and access: Tea and ordinary extracts are inexpensive and widely sold. Cost is not the constraint. Dose form and liver-enzyme checks are.
Interaction with Foundational Habits
-
Sleep: Direction is direct and adverse when the product contains caffeine and is taken late, and largely none for a decaffeinated extract. Mechanism is caffeine, not EGCG. Practical step is morning-only caffeinated tea, or a decaf extract, if sleep is already light.
-
Nutrition: Direction is blunting for non-heme iron when catechins meet the meal, and protective for the liver when an extract is taken with food rather than fasting. Separating iron supplements from tea is the concrete step.
-
Exercise: Direction is a small, indirect potentiation of fat oxidation, not a replacement for training. Meta-analyses of weight show fractions of a kilogram, which is smaller than the effect of a sustained training program. Timing the dose before exercise is optional, not required.
-
Stress management: Direction is none established for cortisol. A small trial of EGCG reported greater calmness on questionnaires (Scholey et al.), but that is not a replicated stress-hormone result. Catechins are not a stress intervention in the current human evidence.
Monitoring Protocol & Defining Success
Before an extract is started, a liver panel, a lipid panel, ferritin, fasting glucose, and a seated blood pressure establish the baseline the small expected shifts will be compared against. Brewed tea at ordinary intakes has not required this panel in the cohort literature. The ongoing cadence for an extract is a repeat ALT at about four weeks, again at about twelve weeks, and then every six to twelve months if the extract continues. Lipids and glucose, if they are the reason for use, are repeated at twelve weeks, when trials typically read those outcomes. Any ALT rise is a reason described for stopping and rechecking, not for pushing the dose. People using only brewed tea more often track how they feel and a routine annual panel than a catechin-specific schedule.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT | <25 U/L | Catches extract-related liver stress early | Fasting not required. Conventional upper limits are often about 33–40 U/L and miss smaller rises. Recheck at about 4 weeks. |
| AST | <25 U/L | Pairs with ALT when a liver signal is suspected | Aspartate aminotransferase (AST, the other common liver enzyme). Conventional upper limits are often about 33–40 U/L. Interpret with ALT, not alone. |
| LDL cholesterol | <100 mg/dL; <70 mg/dL if cardiovascular risk is already high | The lipid outcome catechin trials actually move | Fasting panel preferred. Conventional goals are often <100 or <130 mg/dL by risk category. Expect a change of only a few mg/dL. |
| Ferritin | 50–150 ng/mL | Shows whether meal-time tea is draining iron stores | Conventional ranges often start near 15–30 ng/mL. More informative in menstruating adults and low-meat diets. |
| Fasting glucose | 75–90 mg/dL | Tracks the small glycemic signal | Fasting. Conventional “normal” often extends to 99 mg/dL. Glycated hemoglobin adds a longer window. |
| Blood pressure | <120/80 mmHg | Tracks the roughly 1 mmHg average shift | Seated, repeated. Many clinic goals use <130/80 mmHg. Home readings beat a single office value. |
Qualitative markers:
- Sleep quality, especially if the product contains caffeine
- Nausea or upper-abdominal discomfort in the first weeks
- Yellowing of the skin or eyes, dark urine, or unusual tiredness
- Daytime energy and perceived stress, which trials have not shown as reliable catechin effects
Emerging Research
-
Prostate progression on surveillance: A phase 2 study is testing green tea catechins against progression of prostate cancer in 360 men on close monitoring (NCT04597359). It is active, not recruiting. A clear slowing would strengthen the cancer signal; a null result would weaken it.
-
Defined extract for two years: Another phase 2 trial gives a standardized catechin preparation (Sunphenon 90D, 405 mg) or placebo for 24 months to 115 men with low- to intermediate-grade prostate cancer (NCT04300855). It is built to read both benefit and safety of one extract.
-
Fibroids, as a combination: FATIMA is recruiting about 240 people to test EGCG plus vitamin D3 against fibroid recurrence after surgery (NCT07647198). It studies a combination, not catechins alone, and could move the fibroid question either way.
-
Events, not surrogates: Lipid and pressure meta-analyses show small shifts (Zamani et al.) but not heart attacks or deaths from extracts. A long comparison of extracts versus brewed tea on clinical events could support or erase the longevity inference drawn from cups of tea.
Conclusion
Tea catechins are the plant compounds that green tea leaves keep when the leaf is heated before it browns, led by the most abundant one in the leaf. As a daily drink they are a long-standing habit. As capsules they are a different exposure: more catechin per dose, and a liver pattern that brewed tea does not share.
Trials support a small improvement in cholesterol, a very small drop in blood pressure, and a small loss of body weight. Glucose shifts are smaller still and do not appear in every group studied. Lower mortality and fewer memory problems show up in studies of tea drinking, not in trials of capsules. Cancer findings from observation and from early prevention trials do not agree. None of this is a large effect. For an adult already attending to food, activity, and standard risk markers, the drink has the longer safety record, and liver-enzyme rises are tied to the capsule.
Harms concentrate in high-dose extracts: liver-enzyme rises in a minority, nausea, less iron absorbed when tea meets the meal, and a sharp loss of effect from one heart drug. Evidence quality is uneven. Cholesterol and liver findings rest on many trials. Cancer, memory, and longevity rest mostly on observation of the beverage. The record supports modest shifts in cholesterol and blood pressure, a real liver caution for extracts, and no basis for treating catechin capsules as a longevity drug.